William Blair initiates coverage of Palvella Therapeutics with Outperform rating
William Blair began covering Palvella Therapeutics, assigning an Outperform rating and a $266 price target. The firm highlighted the company's QTORIN platform and the encouraging Phase III trial results for its lead drug, QTORIN rapamycin, in patients with microcystic lymphatic malformations. Palvella expects the first regulatory approval in the first half of 2027, which would move it from a clinical‑stage to a commercial business. The analyst noted the company's strong cash position and projected U.S. sales of about $800 million by 2032.
Why it matters
The rating and price target provide a valuation benchmark for investors, while the anticipated approval could generate significant revenue as the drug enters the market. The firm’s cash balance and low debt give it flexibility to fund launch activities.
Key facts
- 1William Blair assigned an Outperform rating and a $266 price target to Palvella Therapeutics. investing.com
- 2Palvella’s lead product, QTORIN rapamycin, showed encouraging Phase III trial results in microcystic lymphatic malformations. investing.com
- 3The company expects its first FDA approval in the first half of 2027. investing.com
- 4William Blair projects U.S. risk‑adjusted sales of approximately $800 million by 2032, assuming a 90% probability of success. investing.com
- 5Palvella reported a second‑quarter loss of $1.52 per share, wider than the $1.16 loss analysts had expected. investing.com
- 6The company ended the quarter with about $251 million in cash and a current ratio of 21.18. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.